Dr Laurent Audoly joins Pieris
pharmafile | June 9, 2010 | Appointment | Research and Development |Â Â Pieris, appointment, research and developmentÂ
French biotech company Pieris has appointed Dr Laurent Audoly as chief scientific officer.
Dr Audoly was most recently biologics research site lead at Merck & Co, and has both pharma and biotech experience, with extensive expertise in therapeutic protein drug development.
“As a keen proponent of targeted therapeutic technologies, I am excited to join Pieris at a stage where the Anticalin approach is beginning to demonstrate its great therapeutic potential,” he said. “My goal is to combine my experience from big pharma and biotech with the capabilities present at Pieris to bring the full spectrum of R&D operations to the next level.”
Dr Audoly has held research and managerial positions of increasing responsibility, first as senior research scientist in the department of inflammation at Pfizer and then as senior research fellow in the department of pharmacology at Merck & Co.
Following his first stint at Merck Laurent joined MedImmune as director of inflammation R&D before returning to Merck as biologics research site lead.
Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months
TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …






